-transparent.png){kind=logo}
The aim of this study was to compare the bioavailability of two atorvastatin formulations (Divator Drogsan Pharmaceuticals, Ankara, Turkey, as the test formulation, and Lipitor, Pfizer Ireland Pharmaceuticals, Dublin, Ireland, as the reference formulation) in 52 healthy volunteers. The study was conducted using a randomised, single-dose, two-way crossover study with a 2-week washout period between the doses. Since the 90% confidence intervals for Cmax, AUC0-72 and AUC0-proprtional to ratios for both, the parent atorvastatin and its main active metabolite ortho-hydroxy atorvastatin, were within the pre-defined Bioequivalance acceptance limits approved by EMEA, we concluded that the atorvastatin formulation elaborated by Drogsan Pharmaceuticals, was bioequivalent to the Lipitor in its rate and extent of absorption.
L Mendoza, and
M Hajdúch, and
R Plausinaitis, and
V Platílová, and
N Emritte, and
M Svoboda
September 2014,
International journal of clinical pharmacology and therapeutics,
L Mendoza, and
M Hajdúch, and
R Plausinaitis, and
V Platílová, and
N Emritte, and
M Svoboda
September 2016,
Clinical drug investigation,
L Mendoza, and
M Hajdúch, and
R Plausinaitis, and
V Platílová, and
N Emritte, and
M Svoboda
January 1996,
European journal of clinical pharmacology,
L Mendoza, and
M Hajdúch, and
R Plausinaitis, and
V Platílová, and
N Emritte, and
M Svoboda
March 2012,
Zhonghua xin xue guan bing za zhi,
L Mendoza, and
M Hajdúch, and
R Plausinaitis, and
V Platílová, and
N Emritte, and
M Svoboda
January 2018,
Drug design, development and therapy,
L Mendoza, and
M Hajdúch, and
R Plausinaitis, and
V Platílová, and
N Emritte, and
M Svoboda
November 2016,
International journal of clinical pharmacology and therapeutics,
L Mendoza, and
M Hajdúch, and
R Plausinaitis, and
V Platílová, and
N Emritte, and
M Svoboda
April 2005,
Biopharmaceutics & drug disposition,
L Mendoza, and
M Hajdúch, and
R Plausinaitis, and
V Platílová, and
N Emritte, and
M Svoboda
December 2009,
International journal of clinical pharmacology and therapeutics,
L Mendoza, and
M Hajdúch, and
R Plausinaitis, and
V Platílová, and
N Emritte, and
M Svoboda
January 2008,
Arzneimittel-Forschung,
L Mendoza, and
M Hajdúch, and
R Plausinaitis, and
V Platílová, and
N Emritte, and
M Svoboda
July 2003,
Drug development and industrial pharmacy,
